*July 2021*

As research efforts prevail with encouraging therapies designed to overcome resistance to EGFR-directed therapies for patients with advanced non–small cell lung cancer (NSCLC), Sukhmani K. Padda, MD, noted that hope indeed exists for this patient populations.

“There may be strategies after a certain resistance that are going to be helpful across a diversity of mechanisms of resistance,” said Padda, director of thoracic medical oncology at Cedars-Sinai Medical Center. “There are other strategies that are going to be much more specific to the resistance profile in that patient’s particular tumor.”

In an interview with OncLive® during the 22nd Annual International Lung Cancer Congress, a program hosted by Physicians’ Education Resource®, LLC, Padda discussed strategies to overcome EGFR resistance in patients with NSCLC. Read more.

Donate

Support EGFR

Latest Newsletter

Get Social: Twitter

Categories